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| INTRODUC TI ON
Cardiac implantable electronic device (CIED) therapy is an important tool in the management of heart failure with reduced ejection fraction. Implantable cardioverter defibrillators (ICD) are indicated for primary prevention of sudden cardiac death in patients with symptomatic heart failure and left ventricular ejection fraction (LVEF) ≤35% despite optimal medical therapy. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] They are also indicated for secondary prevention in patients who have survived a cardiac arrest or hemodynamically unstable ventricular arrhythmia. 1, [9] [10] [11] [12] [13] [14] Cardiac resynchronization therapy (CRT) is indicated in patients with symptomatic heart failure, sinus rhythm, LVEF ≤35%, and a wide QRS despite optimal medical therapy. 9, 10, [14] [15] [16] [17] [18] This can be de- . 19 The ANZACS-QI DEVICE Registry has been used previously to describe the clinical characteristics and implant details of patients receiving new pacemaker implants. 20 Our study aims to describe the contemporary NZ use of ICD and CRT, utilizing the ANZACS-QI DEVICE Registry. 
| ME THODS
All
| Definitions
Appropriate device therapy was defined as the delivery of antitachycardia pacing (ATP) or shocks for ventricular tachycardia (VT) or ventricular fibrillation (VF). Device therapy in the absence of VT or VF was considered to be inappropriate device therapy. where appropriate. All P-values reported were two-tailed and a P < .05 was considered significant. Data were analyzed using the SAS statistical package, version 9.4 (SAS Institute). Crude implant rates were calculated using the 2017 Projected New Zealand Population.
| Statistical analysis

| Ethics
ANZACS-QI is a substudy within the PREDICT study which was 
| RE SULTS
There were 1579 ICD implants during this study period, including 1152 (73.0%) new implants and 427 (27.0%) replacement procedures.
| New ICD implants
Of the 1152 new implants, there were 565 (49.0%) primary prevention ICDs and 587 (51.0%) secondary prevention ICDs ( 
| Primary prevention CRT defibrillators and CRT pacemakers
The subgroup of new primary prevention CRT-D patients (n = 155) was compared with new CRT-P patients (n = 175). The baseline characteristics are shown in Table 2 . NYHA class and LVEF were recorded in all patients with CRT-P, but only available in those with a history of clinical heart failure (92.3%) in the CRT-D group. Most patients in both primary prevention CRT-D and CRT-P groups had symptomatic heart failure (NYHA ≥II in 89.0% vs 89.2%, P = . The overall complication rate in the first 6 weeks was 9.1%.
Pneumothorax occurred in 1.2% and coronary sinus dissection in 1.2%. Hematoma occurred in 0.6%, with intervention required in 0.3%. The rate of infection was 3.3%, with 0.3% requiring device removal. Reoperation was required in 2.4%, including 2.1% for leadrelated reoperation. Death from any cause at 6 weeks was recorded in one patient (0.3%), but this patient did not have any other devicerelated complications recorded.
| ICD replacements
In the 427 ICD replacements, 72.6% were for elective replacement indicators and 9.6% were for system upgrades ( 
| ICD and CRT national and regional implant rates in 2016
As there was participation from all implant sites in 2016, this pro- 
| D ISCUSS I ON
This is the first study to describe individual level data on ICD and CRT patient characteristics and implant practice at a national level.
Implant volumes and types of pacemakers and ICDs have been surveyed regularly across Australia and NZ previously. 22 In patients who receive ICD and CRT-D, previous reports have examined the impact of geographic, ethnic, and socioeconomic impact on implant rates at a national level, while the long-term outcomes of patients have only been examined at a regional level. 23, 24 Three-quarters of ICD implant procedures in contemporary NZ practice are new implants. Of these, half were for primary prevention indications. The majority of patients receiving a primary prevention ICD had a history of clinical heart failure with significant heart failure symptoms and poor LV systolic function. Most patients receiving secondary prevention ICD were for VT/VF cardiac arrest or sustained VT. CRT-D was the device type in a quarter of patients receiving an ICD for primary prevention indications but fewer than one-tenth of those for secondary prevention indications. Of the ICD replacement procedures, nearly three-quarters were for an elective replacement indication. Nearly half of the patients presenting for an ICD replacement had received at least one appropriate device therapy during the life of the device, and almost a fifth received inappropriate device therapy. There is also significant variation in implant rates and implant practice across the NZ regions, particularly with primary prevention ICD implant ratios and selection of CRT modality.
| New implants-primary vs secondary prevention
The ratio of new primary prevention ICD implants to secondary prevention ICD implants in our cohort was just under 50%. This is essentially unchanged from the last analysis of national ICD implant practice in NZ in 2010. 23 The primary prevention ICD implant ratio reported in several international registries over the past decade is as follows: 46% in Denmark, 55% in Germany, 57% in the United Kingdom, 59% in Sweden, 62% in Spain, 63% in France, 73% in Canada, 75% in the United States, and 82% in Italy. [25] [26] [27] [28] [29] [30] [31] [32] The proportion of ICDs implanted in NZ for primary prevention indications is thus on the lower end of the range of contemporary international implant practice. There is also variation in primary prevention ICD implant ratio of 39%-62% across NZ regions. This suggests that we are relatively conservative with our patient selection, which is likely because of the resource constraints, work force limitations and varying interpretation of the evidence and guidelines by implanting centers in NZ. In accordance with international guideline recommendations, most of the patients receiving a primary prevention ICD in our cohort had a history of clinical heart failure, significant heart failure symptoms and LVEF ≤35%. The clinical characteristics of the patients in our cohort were similar to those described in international registries. 27, 30 The mean LVEF in the primary prevention group was 25.1%, which was similar to several major primary prevention ICD and CRT-D trials that had a mean LVEF of 21.4%-28.0%. [2] [3] [4] [5] [6] [7] 15, 16, 18 Interestingly, ischemic etiology for heart failure accounted for only 42.5% of primary prevention ICD implants and 55.8% of secondary prevention ICD implants in our cohort. This is in contrast to other international studies that have reported ischemic etiology for heart failure at rates of 54.0%-93.0%. 25, [28] [29] [30] This trend may change in the coming years following the results of the DANISH study, which has shown no mortality benefit in primary prevention ICD implantation in nonischemic cardiomyopathy.
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| CRT
Patients who received CRT-P were older and more likely to be female while patients receiving CRT-D had longer mean QRS duration and poorer LV function. There has been limited evidence directly comparing CRT-P to CRT-D, thus current international guidelines do not advocate one modality over the other. In NZ, while the decision to offer CRT-P or CRT-D varies across implant centers, it has been our general practice to limit primary prevention ICD implantation in patients >75 years old. 10 Female gender has been associated with a "super-response" to CRT in previous studies, thus women are also more likely to be offered a CRT-P in NZ. [34] [35] [36] [37] [38] [39] This trend is consistent with several contemporary international registries and studies. [40] [41] [42] [43] Of note, those studies have shown very similar LV systolic function between the CRT-P and CRT-D cohorts, with CRT-P having a longer mean QRS duration. The longer mean QRS duration and poorer LV systolic function in our CRT-D cohort compared to our CRT-P cohort suggests that we are selecting patients with a higher perceived risk for CRT-D.
| ICD replacements
Of those who came for an ICD replacement, over a mean duration of Complications (up to 6 weeks), n (%) 43 (7.6) 23 (3. 
TA B L E 2 New primary prevention CRT-D and CRT-P patient characteristics
CRT-D (n = 155) CRT-P (n = 175) P There is significant regional variation in implant practice across NZ. This is likely to be influenced by physician preference and resource constraints at a local and regional level.
| LI M ITATI O N S
This study is a descriptive analysis of the data within the DEVICE Registry. As a number of implant sites joined and left the registry during the period of analysis, the registry does not contain data of all patients in NZ receiving an ICD or CRT during this study pe- The ANZACS-QI registry is currently being updated to address these limitations.
| CON CLUS ION
In contemporary NZ practice three-quarters of ICD implants were new implants, of which half were for primary prevention indications.
The majority of patients receiving primary prevention and secondary prevention ICD met current international guideline indications. Our 
